Effect of cAMP phosphodiesterase inhibitors on ADP-induced shape change, cAMP and nucleoside diphosphokinase activity of rabbit platelets.
The effects of cAMP phosphodiesterase inhibitors on ADP-induced shape change and cAMP concentrations have been studied. Caffeine (10 mM), theophylline (8 mM), dipyridamole (0.2 mM), or papaverine (0,05 mM) prevented the shape change of washed rabbit platelets induced by 0.4 microM ADP. At these concentrations, none of these cAMP phosphodiesterase inhibitors increased 14C-cAMP in platelets in which the cytoplasmic adenine nucleotides had been labelled with 14C-adenine. By a protein binding assay, only papaverine by itself increased platelet cAMP above its basal level. These results indicate that two pools of cAMP may exist in platelets. Both methods showed that stimulation of platelet adenylate cyclase with PGE1 (1 microM) resulted in an increase in platelet cAMP and all these cAMP phosphodiesterase inhibitors potentiated this increase caused by PGE1. By themselves, some of these compounds may act through mechanisms that do not involve platelet cAMP. The effects of these cAMP phosphodiesterase inhibitors on platelet nucleoside diphosphokinase (NDK) activity were also investigated. At concentrations that prevented ADP-induced shape change, papaverine and dipyridamole had no effect on the formation of 14C-ATP from 14C-ADP by washed rabbit platelets. The methylxanthines partially inhibited NDK activity of washed rabbit platelets and of isolated platelet membranes, probably due to the structural similarity between the adenine ring of ADP and these substances. However, adenine (8 mM) inhibited ADP-induced shape change and platelet NDK activity but was a less effective inhibitor of ADP-induced platelet aggregation. Thus it seems unlikely that interference with platelet NDK or the ADP receptor is the major mechanism by which the methylxanthines inhibit platelet functions.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000244:Adenosine Diphosphate / Q000494:pharmacology*; D000527:Alprostadil; D000818:Animals; D001792:Blood Platelets / Q000187:drug effects* / Q000473:pathology; D000242:Cyclic AMP / Q000097:blood*; D066298:In Vitro Techniques; D009701:Nucleoside-Diphosphate Kinase / Q000097:blood*; D010770:Phosphotransferases / Q000097:blood*; D011458:Prostaglandins E / Q000494:pharmacology; D011817:Rabbits; D013806:Theophylline / Q000494:pharmacology
D011458:Prostaglandins E; D000244:Adenosine Diphosphate; D013806:Theophylline; D000242:Cyclic AMP; D010770:Phosphotransferases; D009701:Nucleoside-Diphosphate Kinase; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D000527:Alprostadil